Purpose and Summary
The National Institute of Standards and Technology (NIST)
has unique analytical capabilities in the safe handling and
identification of illicit drugs. This legislation would direct
NIST to take steps to enhance its work to understand the unique
properties of Tranq and other novel synthetic opioids, develop
new analytical capabilities for novel synthetic opioids, and
establish new partnerships with front-line entities that are
oftentimes the points of first contact for new opioid variants.
Background and Need for Legislation
The development and distribution of novel synthetic opioids
continues to threaten the health and safety of communities
across the United States. A new fentanyl analogue, commonly
known as ``Tranq'', containing a veterinary tranquilizer,
xylazine, has begun to spread across the country. Many law
enforcement agencies, especially in rural America, lack the
technical expertise and resources to safely handle dangerous
substances. While local law enforcement and non-profit agencies
on the East Coast are relatively familiar with the utility of
working with NIST, the agency's work is lesser known as you
move west across the country.
The Drug Enforcement Agency (DEA) reports skyrocketing
detections of xylazine, with growth between 2020 and 2021 at
61% in the Northeast, 198% in the South, 7% in the Midwest, and
112% in the West. According to the DEA, ``the presence of
xylazine in illicit drug combinations and its detection in
fatal overdoses may be more widespread than reported as a
number of jurisdictions across the country may not include
xylazine in forensic laboratory or toxicology testing.''
Directing NIST to leverage its existing expertise and
infrastructure to augment the capabilities of entities working
to counter the opioid crisis will save money for local law
enforcement, enhance safety for law enforcement personnel,
raise awareness of the dangers of fentanyl containing xylazine,
and better prepare first responders for rapid and safe opioid
response activities.
LEGISLATIVE HISTORY
On March 23, 2023, Rep. Mike Collins and Rep. Yadira
Caraveo introduced H.R. 1734, the Testing, Rapid Analysis, and
Narcotic Quality (TRANQ) Research Act.
On March 29, 2023, the Committee on Science, Space, and
Technology met to consider H.R. 1734. Chairman Lucas moved that
Committee favorably report the bill, H.R. 1734, as amended, to
the House of Representatives with the recommendation that the
bill be approved. The motion was agreed to by a vote of 36-0.
COMMITTEE VIEWS
The Committee recognizes the impact of the opioid crisis on
everyday Americans and first responders tasked with providing
emergency services to those in need. The Committee is also
aware of the unique capabilities of NIST to identify chemical
markers of novel synthetic opioids and develop safe handling
practices that can inform first response efforts. The Committee
encourages NIST to continue its work with novel synthetic
opioids and other illicit drugs and to grow its partnerships
with first responders across the nation who could benefit from
NIST's expertise.
SECTION-BY-SECTION
Section 1. Short title
This section establishes that this legislation may be
referred to as the ``Testing, Rapid Ananysis, and Narcotic
Quality Research Act'' or the ``TRANQ Research Act.''
Section 2. Xylazine detection and analysis
This section directs NIST to conduct basic science and
research on illicit drugs, with a special focus on drugs
containing xylazine. It also directs NIST to work towards near-
real time identification capabilities of xylazine in drugs,
convene stakeholders with unique knowledge or interests in
counter-opioid efforts, establish collaborative partnerships
with other institutions, including research institutions, and
provide opportunities for graduate and post-graduate research
on xylazine-laced drugs. In fulfilling the requirements of this
section, NIST must ensure there are appropriate research
security controls.
Section 3. Report
NIST must submit a report to the Committee on Science,
Space, and Technology one year after the date of enactment on
the implementation of this act, including legislative
recommendations for improving NIST's ability to carry out the
act.
EXPLANATION OF AMENDMENTS
An amendment offered by Representative Claudia Tenney was
adopted by voice vote and is incorporated in the Committee
reported text of H.R. 1734. The amendment requires NIST to
report on the effectiveness of the legislation one year after
enactment, and allows NIST to include recommendations for how
to improve the effort as part of the reporting requirement.
This amendment is consistent with the spirit of the legislation
and will inform Congressional oversight of NIST's efforts in
the future.
Committee Consideration
On March 29, 2023, the Committee met in open session and
ordered reported favorably the bill, H.R. 1734, as amended, by
roll call vote, a quorum being present.
ROLL CALL VOTES
Clause 3(b) of rule XIII requires the Committee to list the
record votes on the motion to report legislation and amendments
thereto. The following reflects the record votes taken during
the Committee consideration:
[GRAPHIC(S) NOT AVAILABLE IN TIFF FORMAT]
APPLICATION OF LAW TO THE LEGISLATIVE BRANCH
The Committee finds that H.R. 1734 does not relate to the
terms and conditions of employment or access to public services
or accommodations within the meaning of section 102(b)(3) of
the Congressional Accountability Act (Public Law 104-1).
STATEMENT OF OVERSIGHT FINDINGS AND RECOMMENDATIONS
OF THE COMMITTEE
In compliance with clause 3(c)(1) of rule XIII and clause
(2)(b)(1) of rule X, the Committee's oversight findings and
recommendations are reflected in the descriptive portions of
this report.
STATEMENT OF GENERAL PERFORMANCE GOALS AND OBJECTIVES
In accordance with clause 3(c)(4) of rule XIII, H.R. 1734
would expand upon NIST's current research and testing of novel
synthetic opiods and other illicit drugs, including xylazine,
in order to continue to grow its partnerships with first
responders across the nation and to develop safety practices
which will inform those first response efforts. A yearly
reporting requirement ensures that the goals of the Committee
are being met and provides an avenue for recommending
legislation to improve NIST's ability to carry out these goals.
DUPLICATION OF FEDERAL PROGRAMS
Pursuant to clause 3(c)(5) of rule XIII, the Committee
finds that no provision of H.R. 1734 establishes or
reauthorizes a program of the Federal Government known to be
duplicative of another Federal program, including any program
that was included in a report to Congress pursuant to section
21 of Public Law 111-139 or identified in the most recent
Catalog of Federal Domestic Assistance.
FEDERAL ADVISORY COMMITTEE ACT
The Committee finds that the legislation does not establish
or authorize the establishment of an advisory committee within
the definition of section 5(b) of the Federal Advisory
Committee Act.
UNFUNDED MANDATE STATEMENT
The Committee adopts as its own the estimate of Federal
mandates prepared by the Director of the Congressional Budget
Office pursuant to section 423 of the Unfunded Mandates Reform
Act.
EARMARK IDENTIFICATION
Pursuant to clauses 9(e), 9(f), and 9(g) of rule XXI, the
Committee finds that H.R. 1734 does not include any
congressional earmarks, limited tax benefits, or limited tariff
benefits.
COMMITTEE COST ESTIMATE
Pursuant to clause 3(d)(1) of rule XIII, the Committee
adopts as its own the cost estimate prepared by the Director of
the Congressional Budget Office pursuant to section 402 of the
Congressional Budget Act of 1974. At the time this report was
filed, the estimate was not available.
NEW BUDGET AUTHORITY, ENTITLEMENT AUTHORITY,
AND TAX EXPENDITURES
Pursuant to clause 3(c)(2) of rule XIII, the Committee
finds that H.R. 1734 would result in no new or increased budget
authority, entitlement authority, or tax expenditures or
revenues.
CONGRESSIONAL BUDGET OFFICE COST ESTIMATE
Pursuant to clause 3(c)(3) of rule XIII, at the time this
report was filed, the cost estimate prepared by the Director of
the Congressional Budget Office pursuant to section 402 of the
Congressional Budget Act of 1974 was not available.
[all]